Pancreatic Cancer Research

ResearcherFirst Affiliated Hospital of GuangXi Medical UniversityNo recent work listed

Xinping Ye

Matched on ORCID iD 0000-0003-2990-9333; OpenAlex author ID A5101731074. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
9
Papers, trials and grants by year

2019: 3 papers · 2020: 3 papers · 2021: 2 papers · 2022: none · 2023: 1 paper

Papers 9

  1. Comprehensive analysis of LILR family genes expression and tumour-infiltrating immune cells in early-stage pancreatic ductal adenocarcinoma. Co-author DOI 10.1049/syb2.12058↗
  2. Prognostic value and potential molecular mechanism of the like-Sm gene family in early-stage pancreatic ductal adenocarcinoma. Co-author DOI 10.21037/tcr-20-3056↗
  3. UXT antisense RNA 1 sever as a novel prognostic long non-coding RNA in early stage pancreatic ductal adenocarcinoma patients after receiving pancreaticoduodene… Co-author DOI 10.7150/jca.46084↗
  4. Noteworthy prognostic value of phospholipase C delta genes in early stage pancreatic ductal adenocarcinoma patients after pancreaticoduodenectomy and potential… Co-author DOI 10.1002/cam4.2699↗
  5. Prognostic value of Glypican family genes in early-stage pancreatic ductal adenocarcinoma after pancreaticoduodenectomy and possible mechanisms. Co-author DOI 10.1186/s12876-020-01560-0↗
  6. Genome-wide RNA-sequencing dataset reveals the prognostic value and potential molecular mechanisms of lncRNA in non-homologous end joining pathway 1 in early s… Co-author DOI 10.7150/jca.39888↗
  7. Prognostic value of Kinesin-4 family genes mRNA expression in early-stage pancreatic ductal adenocarcinoma patients after pancreaticoduodenectomy. Last author DOI 10.1002/cam4.2524↗
  8. Cystatin F as a key family 2 cystatin subunit and prognostic biomarker for early‑stage pancreatic ductal adenocarcinoma. Co-author DOI 10.3892/or.2019.7135↗
  9. Clinical significance and prospective molecular mechanism of C‑C motif chemokine receptors in patients with early‑stage pancreatic ductal adenocarcinoma after … Co-author DOI 10.3892/or.2019.7277↗

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xiwen Liao · 9 shared papers, 2019–2023 · strength 0.94
  2. Tao Peng · 9 shared papers, 2019–2023 · strength 0.94
  3. Chengkun Yang · 8 shared papers, 2019–2023 · strength 0.82
  4. Xin Zhou · 7 shared papers, 2019–2021 · strength 0.69
  5. Quan‐Fa Han · 4 shared papers, 2019–2020 · strength 0.34
  6. Junqi Liu · 3 shared papers, 2019–2020 · strength 0.25
  7. Zijun Chen · 2 shared papers, 2020–2021 · strength 0.22
  8. Liming Shang · 2 shared papers, 2019–2020 · strength 0.18
  9. Qiang Gao · 1 shared paper, 2023 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.